Literature DB >> 15765394

HNPCC-associated small bowel cancer: clinical and molecular characteristics.

Karsten Schulmann1, Frank E Brasch, Erdmute Kunstmann, Christoph Engel, Constanze Pagenstecher, Holger Vogelsang, Stefan Krüger, Tilman Vogel, Hanns-Peter Knaebel, Josef Rüschoff, Stephan A Hahn, Magnus V Knebel-Doeberitz, Gabriela Moeslein, Stephen J Meltzer, Hans K Schackert, Christiane Tympner, Elisabeth Mangold, Wolff Schmiegel.   

Abstract

BACKGROUND & AIMS: The risk for small bowel cancer (SBC) is significantly increased in hereditary nonpolyposis colorectal cancer (HNPCC). HNPCC-associated SBCs are poorly characterized.
METHODS: Thirty-two SBCs were characterized according to clinical, pathologic, and germline mutation data. Histomorphologic characteristics, microsatellite instability (MSI) testing, mismatch repair (MMR) protein expression, and frameshift mutations of 7 coding mononucleotide repeats were investigated in 17 SBCs.
RESULTS: Median age at diagnosis was 39 years. Fifty percent of SBCs were located in the duodenum. The Amsterdam criteria were fulfilled in 50% of patients; 45% of patients had no personal history of previous malignancies. Two patients had a positive family history for SBC. Pathogenic germline mutations were identified in 81%; high MSI was detected in 95% and loss of MMR protein expression in 89% of cases. TGFBR2 , BAX , MSH3 , MSH6 , ACVR2 , AIM2 , and SEC63 frameshift mutations were detected in 69%, 59%, 59%, 35%, 82%, 56%, and 56%, respectively. An expansive growth pattern of the tumor border and an intense intratumoral lymphocytic infiltrate were present in 75%, respectively.
CONCLUSIONS: HNPCC-associated SBC often manifests at a young age and may be the first disease manifestation. Endoscopy may detect 50% of tumors. Considering recent data on gastric cancer, we propose endoscopic screening of mutation carriers starting at 30 years of age because clinical criteria cannot define a high-risk group. In addition, our study shows that histopathologic criteria, MSI, and MMR immunohistochemistry are often similar to these features in HNPCC.

Entities:  

Mesh:

Year:  2005        PMID: 15765394     DOI: 10.1053/j.gastro.2004.12.051

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  57 in total

Review 1.  AIM2 inflammasome in infection, cancer, and autoimmunity: Role in DNA sensing, inflammation, and innate immunity.

Authors:  Si Ming Man; Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Eur J Immunol       Date:  2015-12-28       Impact factor: 5.532

Review 2.  Inflammasomes and intestinal inflammation.

Authors:  N Zmora; M Levy; M Pevsner-Fishcer; E Elinav
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

3.  Metachronous small bowel adenocarcinomas detected by capsule endoscopy in a patient with hereditary nonpolyposis colorectal cancer.

Authors:  Matthew M Baichi; Razi M Arifuddin; Parvez S Mantry
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

Review 4.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

Review 5.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 6.  Immunobiology and structural biology of AIM2 inflammasome.

Authors:  Bing Wang; Madhurima Bhattacharya; Sayantan Roy; Yuan Tian; Qian Yin
Journal:  Mol Aspects Med       Date:  2020-07-10

7.  [Standards for diagnostics and therapy of gastric cancer].

Authors:  N Schulte; M Ebert
Journal:  Internist (Berl)       Date:  2014-08       Impact factor: 0.743

8.  DNA Sensing in the Innate Immune Response.

Authors:  Benoit Briard; David E Place; Thirumala-Devi Kanneganti
Journal:  Physiology (Bethesda)       Date:  2020-03-01

Review 9.  Role of AIM2 inflammasome in inflammatory diseases, cancer and infection.

Authors:  Bhesh Raj Sharma; Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Eur J Immunol       Date:  2019-08-14       Impact factor: 5.532

10.  Evolutionary gain of function for the ER membrane protein Sec62 from yeast to humans.

Authors:  Linda Müller; Maria Diaz de Escauriaza; Patrick Lajoie; Melanie Theis; Martin Jung; Anika Müller; Carsten Burgard; Markus Greiner; Erik L Snapp; Johanna Dudek; Richard Zimmermann
Journal:  Mol Biol Cell       Date:  2010-01-13       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.